Catalent Completes $25M Upgrade To Schorndorf Site, Featuring Expanded Storage And New FastChain Area

7/16/24 2:29:42 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $CTLT alert in real time by email

The expansion increases the site's footprint by 32,000 square feet (3,000 square meters), adding storage and handling of clinical trial supply materials at controlled room temperatures between 15 and 25 degrees Celsius. It also creates space in the original building to accommodate the installation of a new, fully automatic bottle filling line, as well as a dedicated area for Catalent's FastChain® demand-led supply service. These added capabilities will support a continued high level of service to Catalent's pharma and biotech customers and the patients they serve.

Get the next $CTLT alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$CTLT

Date	Price Target	Rating	Analyst
11/16/2023	$45.00 → $53.00	Neutral → Outperform	Robert W. Baird
9/5/2023	$62.00	Hold → Buy	Argus
7/20/2023	$43.00	Equal Weight	Wells Fargo
7/5/2023	$45.00	Neutral	JP Morgan
6/14/2023	$45.00 → $44.00	Buy → Hold	Jefferies
5/22/2023	$90.00 → $45.00	Overweight → Neutral	JP Morgan
5/15/2023	$55.00 → $29.00	Buy → Hold	Deutsche Bank
5/8/2023	$28.00	Neutral → Underperform	BofA Securities

More analyst ratings

$CTLT
Press Releases

Fastest customizable press release news feed in the world

Catalent, Inc. Reports First Quarter Fiscal 2025 Results
Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1'25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA(1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fisc
11/5/24 7:00:00 AM ET
$CTLT
Biotechnology: Pharmaceutical Preparations
Health Care
Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings
Committed to Continuing to Serve Customers and Patients as a Leading Global, Independent, Full-Service CDMO Post-Close Alessandro Maselli to Remain President and CEO of Catalent Post-Close Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today issued the following open letter to customers: To Catalent's Valued Customers, I want to correct a few key inaccuracies that have been reported in the press regarding Novo Holdings' pending acquisition of Catalent and reiterate that we are, and will continue to be, driven by our mission to develop, manufacture and supply products that help people live better and healthier li
10/21/24 7:00:00 AM ET
$CTLT
Biotechnology: Pharmaceutical Preparations
Health Care
Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility
Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in Somerset, NJ to Ardena, a Contract Development and Manufacturing Organization (CDMO) with locations in Belgium, Spain, the Netherlands and Sweden. Financial details of the agreement, which is expected to close in early 2025, have not been disclosed. The Somerset facility also houses Catalent's corporate headquarters, which in the near term will remain at the Somerset site during a transition period before shifting to a new locati
10/14/24 6:00:00 AM ET
$CTLT
Biotechnology: Pharmaceutical Preparations
Health Care

Catalent, Inc. Reports First Quarter Fiscal 2025 Results
Q1'25 net revenue of $1.02 billion increased 4% as reported and in constant currency(1), compared to Q1'24. Q1'25 net revenue, excluding COVID revenue of ~$30 million in Q1'25 and ~$100 million in Q1'24, increased 13% compared to Q1'24. Q1'25 net loss of $(129) million. Q1'25 Adjusted EBITDA(1) of $125 million increased 11% as reported, or 10% in constant currency, compared to Q1'24. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for the first quarter of fisc
11/5/24 7:00:00 AM ET
$CTLT
Biotechnology: Pharmaceutical Preparations
Health Care
Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results
Q4'24 net revenue of $1.30 billion increased 23% as reported, or 24% in constant currency, compared to Q4'23. Organic, constant-currency net revenue increased 24%, compared to Q4'23. Q4'24 net revenue, excluding COVID-related revenue of ~$70 million in Q4'23 and ~$30 million in Q4'24, increased 29% compared to Q4'23. Fiscal 2024 net revenue of $4.38 billion increased 3% as reported, or 2% in constant currency, compared to fiscal 2023. Organic, constant-currency net revenue increased 1% compared to FY'23. FY'24 net revenue, excluding COVID-related revenue of ~$630 million in FY'23 and ~$260 million in FY'24, increased 13% compared to FY'23. Q4'24 net earnings of $23 million
8/29/24 7:30:00 AM ET
$CTLT
Biotechnology: Pharmaceutical Preparations
Health Care
Catalent, Inc. Reports Third Quarter Fiscal 2024 Results
Q3'24 net revenue of $1.07 billion increased 4% as reported, or 3% in constant currency(1), compared to Q3'23. Q3'24 net revenue, excluding COVID-related revenue of ~$120 million in Q3'23 and ~$60 million in Q3'24, increased 11% compared to Q3'23. Q3'24 net loss of $(101) million compared to $(227) million of net loss in Q3'23. Q3'24 Adjusted EBITDA(1) of $163 million increased 55% as reported, or 53% in constant currency, compared to Q3'23. (1) See "Non-GAAP Financial Measures" below and the GAAP to non-GAAP reconciliation provided later in this release. Catalent, Inc. (NYSE:CTLT) ("Catalent"), the leader in enabling the development and supply of better treatments for patien
5/8/24 4:15:00 PM ET
$CTLT
Biotechnology: Pharmaceutical Preparations
Health Care

$CTLT
Leadership Updates

Live Leadership Updates

Ardena appoints Jeremie Trochu as Chief Executive Officer
GHENT, Belgium, June 6, 2024 /PRNewswire/ -- Ardena (the "Company") today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive Officer. Jeremie is a seasoned executive in the pharmaceutical Contract Development and Manufacturing Operations (CDMO) industry. Harry will step down as CEO after 20 years of leading the Company, remaining on Ardena's Board. Jeremie brings an extensive knowledge of the life sciences and CDMO industry, and a proven track record of success in the biopharma sector, with 20 years of experience in building and growing businesses globally, expanding into new markets, and leading large-scale transformations
6/6/24 10:00:00 AM ET
$CTLT
Biotechnology: Pharmaceutical Preparations
Health Care
Sotera Health Appoints Karen Flynn to Board of Directors
CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal
11/13/23 7:00:14 AM ET
$CTLT
$QTRX
$SHC
$WST
Biotechnology: Pharmaceutical Preparations
Health Care
Biotechnology: Laboratory Analytical Instruments
Industrials
ViroCell Expands Business Development Team to Support Next Phase of Growth
Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell's business in the US and Europe Team ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023 ViroCell Biologics ("ViroCell" or the "Company"), a specialist contract development and manufacturing organisation ("CDMO") in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe). Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCel
10/4/23 2:00:00 AM ET
$CTLT
$TMO
Biotechnology: Pharmaceutical Preparations
Health Care
Industrial Machinery/Components
Industrials

Catalent Completes $25M Upgrade To Schorndorf Site, Featuring Expanded Storage And New FastChain Area

Chat with this insight

Recent Analyst Ratings for $CTLT

$CTLT Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13G/A filed by Catalent Inc.

Amendment: SEC Form SC 13G/A filed by Catalent Inc.

Amendment: SEC Form SC 13G/A filed by Catalent Inc.

$CTLT Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Catalent upgraded by Robert W. Baird with a new price target

Catalent upgraded by Argus with a new price target

Wells Fargo initiated coverage on Catalent with a new price target

$CTLT Press Releases

Fastest customizable press release news feed in the world

Catalent, Inc. Reports First Quarter Fiscal 2025 Results

Catalent Issues Open Letter to Customers Regarding Pending Acquisition by Novo Holdings

Catalent Signs Agreement to Sell Somerset, NJ Oral Solids Facility

$CTLT SEC Filings

SEC Form 10-Q filed by Catalent Inc.

Catalent Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

Amendment: SEC Form 10-K/A filed by Catalent Inc.

$CTLT Financials

Live finance-specific insights

$CTLT Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CTLT Market Insights

Live Market Insights

Catalent, Inc. Reports First Quarter Fiscal 2025 Results

Catalent, Inc. Reports Fourth Quarter and Fiscal 2024 Results

Catalent, Inc. Reports Third Quarter Fiscal 2024 Results

Director Ryan Michelle R sold $167,160 worth of shares (2,800 units at $59.70), decreasing direct ownership by 21% to 10,835 units (SEC Form 4)

Director Barg Steven was granted 4,663 shares, increasing direct ownership by 60% to 12,374 units (SEC Form 4)

Director Ryan Michelle R was granted 4,663 shares, increasing direct ownership by 52% to 13,635 units (SEC Form 4)